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Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer.
Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of
survival after neoadjuvant therapy. Thus, pathological complete response has become a primary end point for
clinical trials. However, there is a current lack of uniformity in the definition of pathological complete response.
A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites
involved in such trials identified marked variability in specimen handling and histologic reporting. An
international working group was convened to develop practical recommendations for the pathologic assessment
of residual disease in neoadjuvant clinical trials of breast cancer and information expected from pathology
reports. Systematic sampling of areas identified by informed mapping of the specimen and close correlation with
radiological findings is preferable to overly exhaustive sampling, and permits taking tissue samples for
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translational research. Controversial areas are discussed, including measurement of lesion size, reporting of
lymphovascular space invasion and the presence of isolated tumor cells in lymph nodes after neoadjuvant
therapy, and retesting of markers after treatment. If there has been a pathological complete response, this must
be clearly stated, and the presence/absence of residual ductal carcinoma in situ must be described. When there
is residual invasive carcinoma, a comment must be made as to the presence/absence of chemotherapy effect in
the breast and lymph nodes. The Residual Cancer Burden is the preferred method for quantifying residual
disease in neoadjuvant clinical trials in breast cancer; other methods can be included per trial protocols and
regional preference. Posttreatment tumor staging using the Tumor–Node–Metastasis system should be included.
These recommendations for standardized pathological evaluation and reporting of neoadjuvant breast cancer
specimens should improve prognostication for individual patients and allow comparison of treatment outcomes
within and across clinical trials.
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Neoadjuvant systemic therapy is being increasingly
used in the treatment of early-stage breast cancer.
Response, in the form of pathological complete
response, is being put forward as an evaluable end
point for determining the efficacy of new agents in
neoadjuvant clinical trials1 and is an excellent
prognostic indicator.2 Data are also emerging on the
frequency of regional recurrence based on the
presence of residual disease in both breast and
lymph nodes.3 However, accurate evaluation of the
original tumor bed depends on correct localization
and sampling of the tumor bed. Therefore, gross
pathologic methods are the single greatest determi-
nant for accurate definition of pathological complete
response or residual disease. This not only alters the
end point, but could increasingly affect decisions
regarding the need for further local–regional or
systemic therapy, if based on the extent of residual
disease.3 Therefore, a standard approach to the
evaluation of the postneoadjuvant systemic therapy
surgical specimen is essential.
Several classification systems have been devel-
oped for the assessment of pathologic response to
neoadjuvant systemic therapy; these have been
reviewed elsewhere.4–11 Although, collectively, they
have their advantages and disadvantages, most have
been validated as correlating with outcome (overall
survival, event-free survival, and/or distant relapse-
free survival).6,10,12–16 However, different staging
systems yield different estimates of future risk.17
The Residual Cancer Burden is an online tool for
the quantification of residual disease that is simple
to apply, reproducible, and has been clinically
validated with long-term follow-up data.10,18,19
Moreover, novel classification systems are con-
tinually being developed, for example, those that
incorporate biomarkers in addition to traditional
histologic prognostic variables, such as the Residual
Proliferative Cancer Burden that combines Residual
Cancer Burden with posttreatment Ki67 index.20
There are also combined clinical and pathological
systems that take into account pretreatment informa-
tion such as clinical stage as well as posttreatment
pathology findings, for example, the ‘clinical-patho-
logic stage–estrogen/grade’ staging system.21 These
approaches also show promise as future means to
predict outcome by combining additional clinical or
biological information with Residual Cancer Burden
or American Joint Committee on Cancer stage after
treatment.
National guidelines have been developed for
histopathologic assessment of breast cancer speci-
mens in individual countries/regions, including
Australasia,22 Belgium,23 Germany,24 the United
Kingdom (now being updated),25 The Netherlands,26
and the United States.27 These vary in their approach
to evaluating the postneoadjuvant specimen.
Frequently, neoadjuvant systemic therapy will be
administered in the setting of a clinical trial.
Pathologists must be involved at an early stage in
trial development so that specimen handling, report-
ing, and tissue collection is specified.28 Currently, in
many multicenter neoadjuvant systemic therapy
trials, the surgical specimens are reported by the
treating hospital without even minimum guidelines
for specimen handling or centralized review to
ensure validity and reproducibility of results. A
central review of histopathology reports within the
neo-tAnGo trial, a UK-based multicenter randomized
neoadjuvant chemotherapy trial in early breast can-
cer, revealed huge variation in handling and reporting
of neoadjuvant specimens between centers.29 In the
I-SPY 1 trial, the pathological complete response rate
fell by almost 10% among pathologists at 9 centers
after they were trained on how to use the Residual
Cancer Burden tool (Laura Esserman, personal com-
munication, 2 August 2013). In a French multicenter
study that used the Chevallier system,30 the patholog-
ical complete response rate in one arm of the study
fell from 16 to 8% following central pathology review
of slides.31
Finally, the definition of pathological complete
response has not been uniform, making reporting
and interpretation of data challenging.5,32 The
frequency of use of different definitions of patho-
logical complete response in major neoadjuvant
clinical trials is illustrated in Figure 1. These
different definitions of pathological complete re-
sponse can change the apparent survival benefit
associated with pathological complete response,
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depending upon which definition is used.
(Figure 2).2,10,15,32,33 There is general consensus that
residual disease in the axillary lymph nodes indi-
cates a worse prognosis, even when there has been
a pathological complete response in the breast,
and hence the definition of pathological complete
response should include absence of disease in both
the breast and axillary lymph nodes.2,3,17,32,34–40
A more contentious issue is whether the presence of
residual ductal carcinoma in situ (DCIS) in the absence
of residual invasive disease should be included or
excluded from pathological complete response.32,33
The US Food and Drug Administration-led pooled
analysis of 12 neoadjuvant randomized trials with
long-term follow-up undertaken by the Collaborative
Trials in Neoadjuvant Breast Cancer (CTNeoBC) found
similar event-free survival and overall survival in
patients without residual invasive carcinoma regard-
less of the presence/absence of residual DCIS.2
However, in a different statistical approach, a pooled
analysis of the seven prospective neoadjuvant sys-
temic therapy clinical trials by the German and
Austrian Breast Groups demonstrated significantly
worse event-free survival for patients with ypTisypN0
compared with patients who were ypT0ypN0. There
was no significant difference in overall survival32
(Figure 2). An analysis of a smaller cohort of patients
treated at the MD Anderson Cancer Center, however,
showed no difference in survival between patients
with ypT0ypN0 and ypTisypN0 (Figure 2).33 It is
conceivable that an internationally uniform procedure
for handling and reporting on postneoadjuvant sys-
temic therapy specimens would eventually resolve
this issue.
Overall, the US Food and Drug Administration-
supported pooled analysis was not able to validate
differences in pathological complete response rate as
a surrogate end point for difference in event-free
survival from the neoadjuvant clinical trials included
in the analysis. However, it did point to substantial
improvements in survival in individuals with patho-
logical complete response and supported standardi-
zation of the definition of pathological complete
response, proposing it should be defined as either
ypT0/isypN0 or ypT0ypN0 in future trials.2
Materials and methods
Given the lack of consensus regarding the patholog-
ical assessment of postneoadjuvant systemic therapy
breast cancer specimens in clinical trials, an inter-
national working group of pathologists, radiologists,
surgeons, medical and radiation oncologists, and
gynecologists was convened by the BIG-NABCG
collaboration. Members were nominated by
BIG-NABCG leadership and the working group
co-chairs, as well as by sites responding to the collec-
tion of standard operating procedures described
below. Members represented an array of disciplines
and countries.
First, to gauge existing variability in approaches to
postneoadjuvant systemic therapy pathologic assess-
ment, we collected standard operating procedures
from neoadjuvant breast cancer trials and from
sites participating in such trials. ClinicalTrials.gov
was searched for mainly academic, phase II or III
neoadjuvant trials activated since 2005, with a
planned recruitment of at least 100 patients. Earlier
trials were included if they were one of the trials
included in the US Food and Drug Administration
pooled analysis noted above, or otherwise were
major trials (e.g., 41000 patients). Standard operat-
ing procedures were requested of 48 trials, both from
the leaders of the trials themselves (trial standard
operating procedures) and, where leaders responded,
the sites involved in those trials (site-specific standard
operating procedures). Information from the standard
operating procedures was abstracted into categories of
‘extent of sampling,’ ‘quantification/size/grading/cellu-
larity,’ ‘lymph node evaluation,’ ‘retesting of markers,’
and ‘other information.’ The abstracted information
was then compared and contrasted.
The working group convened on seven teleconfer-
ences and three smaller planning calls, exchanged
emails, and went through several rounds of com-
ments, resulting in the development of practical
recommendations for a minimum, essential set of
components that should be included in the pathologic
evaluation and reporting of postneoadjuvant systemic
therapy breast cancer specimens. The working group
has also written a companion paper intended for a
Figure 1 Use of different definitionsa of pathological complete
response in major neoadjuvant breast cancer clinical trials. Trials
included in graphic above: first bar: GeparDuo, GeparTrio,
GeparQuattro, GeparQuinto, GeparSixto, GeparSepto, NEOCENT;
second bar: ABCSG 32, ACOSOG-Z1031, ACOSOG-Z1071, ARTe-
mis, CHERLOB, CNIO-BR-01 2010, I-SPY 2, MDACC 2012-0167,
neo-tAnG0, neo-TN (used Neoadjuvant Response Index), NEO-
ZOTAC, NOAH, REMAGUS 02, S0800, TECHNO; third bar:
ACOSOG-Z1041, AGO1, CALGB-40601, CALGB-40603, ECTO,
GEICAM/2006-14, Neo-ALTTO, Neo-Sphere, NSABP-B-18,
NSABP-B-27, NSABP-B-40, NSABP-B-41, S0012; fourth bar:
EORTC-10994. aDefinition used in the primary end point or,
where pathological complete response was not the primary end
point, in the secondary end point.
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more multidisciplinary audience, explaining how a
standardized approach would benefit the entire
medical team and summarizing the more detailed
recommendations provided below.41
Results
Standard operating procedures were collected from
28 trials and 25 sites (Supplementary Information 1).
Substantial variability of practice was found in all
stages of histological evaluation of both breast and
nodal neoadjuvant specimens: extent of sampling
(ranging from 4 to 40 blocks, depending on presence/
absence of a macroscopic identifiable lesion and on
tumor size), thickness of primary-tumor sectioning
(ranging from 2 to 10mm), the routine performance
of immunohistochemical staining when no tumor
was identified on hematoxylin and eosin, how
amount of residual tumor was measured and
documented, and whether or not a formal system
was used to grade response and, if so, which system
was used. For small specimens, most sites submitted
the entire specimen. Only 6 of 20 sites that discussed
retesting of markers in their response noted they
retested markers routinely. Of note, several sites
emphasized a need for standardization of the patho-
logic assessment of postneoadjuvant systemic therapy
specimens, within practicable limits. Further details
are provided in Supplementary Information 1.
Recommendations
The working group’s practical suggestions are
detailed below.
Pretreatment Assessments
Initial diagnosis on core biopsy of the breast
Percutaneous image-guided core needle biopsy is
strongly recommended, and must be adequate for an
unequivocal diagnosis of invasive breast carcinoma.
Caution must be used if imaging or core needle
biopsy findings suggest that a significant portion of
the lesion may represent in situ disease, or if there is
only a limited amount of invasive carcinoma repre-
sented in the core. In these cases, repeat core needle
Figure 2 Survival curves showing impact of different definitions of pathological complete response on survival. (a) Data from the German
Breast Group and AGO-B trials pooled analysis showing reduced disease-free survival for patients with ypTisypN0 vs ypT0ypN0. Patients
who had residual nodal disease despite absence of invasive cancer in the breast (ypT0/isypN+) had the poorest disease-free survival.32
(b) Results from the same study showing no significant difference in overall survival between ypT0ypN0 and ypTisypN0. The ypT0/isypN+
has a significantly worse overall survival compared with ypT0/isypN0. (c) In the CTNeoBC pooled analysis,2 ypT0pN0 and ypT0/isypN0
were more strongly associated with improved event-free survival and overall survival than ypT0/is alone. Moreover, ypT0ypN0 and ypT0/
isypN0 were similar in their associations to event-free survival and overall survival. (d) MD Anderson study showing 5- and 10-year
overall survival (left) and disease-free survival (right) rates were identical for the patients with pathological complete response vs
pathological complete response+DCIS.33 (e) Categories of reduction in cellularity in the Miller–Payne system correlate with disease-free
survival.15 (f) Residual Cancer Burden score is an independent variable that predicts likelihood of relapse. Minimal residual disease (RCB-
I) carries the same prognosis as pathological complete response.10 (a and b) Reprinted with permission. © 2012 American Society of
Clinical Oncology. All rights reserved. von Minckwitz et al.32 (c) Reprinted from Cortazar et al.2 © 2014 with permission from Elsevier. (d)
Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved. Mazouni et al.33 (e) Reprinted from Ogston
et al.15 © 2003, with permission from Elsevier. (f) Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights
reserved. Symmans et al.10
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biopsy or surgery for accurate diagnosis, rather than
neoadjuvant systemic therapy, may be indicated.
Histologic type, tumor grade, estrogen receptor (ER),
progesterone receptor (PR), and HER2 status, as well
as any other parameters used to select for neoadju-
vant systemic therapy (e.g., Ki67, multigene assays)
should be evaluated on the core needle biopsy.
Several systems for grading tumor response to
treatment require comparison of cellularity with the
pretreatment biopsy, such as the Miller–Payne,
Pinder, Sinn, and Sataloff systems.7,13,15,42 Inclusion
of an estimate of tumor cellularity in the core needle
biopsy is of value if these systems will be used to
grade response in the excision specimen.
Consideration should be given to dedicated base-
line cores for research, either at the time of
diagnostic biopsy or as a separate designated biopsy
procedure.43 Research cores should be in addition to
those required for diagnosis and should be preserved
in order to best meet the research need. Touch
preparations or frozen sections can be used to
confirm the presence of malignant cells in the
dedicated research cores before freezing or immer-
sion into a dedicated solution. If using Optimum
Cutting Temperature freezing media, one tissue core
can be embedded per block. In some cases, formalin-
fixed cores can be reembedded as a research block
after reporting. Some trials also require ‘on-treat-
ment’ research core biopsies at subsequent time
points (e.g., after the first cycle or at mid-course).
Evaluation of the axilla before treatment
Routine axillary ultrasound is recommended to
assess the axillary lymph nodes, with fine needle
aspiration or core needle biopsy of morphologically
abnormal lymph nodes. Thus, sentinel lymph node
biopsy before neoadjuvant treatment should be
limited to cases where the pretherapeutic lymph
node status is required for systemic or local
treatment decisions.44 Pretreatment sentinel lymph
node biopsy precludes assessment of nodal response
to neoadjuvant systemic therapy, and invalidates
American Joint Committee on Cancer yp stage and
calculation of the Residual Cancer Burden score if an
excised sentinel lymph node was originally positive.
Evaluation of the Surgical Specimen After
Neoadjuvant Systemic Therapy
Clinical information required for pathologic
evaluation
It is important that the multidisciplinary team (e.g.,
surgeons, radiologists, and pathologists) communi-
cate as a team for patient care; this is covered in
detail in our companion multi-disciplinary paper.41
At a bare minimum, the request form must clearly
indicate neoadjuvant systemic therapy has been
given, along with the location and pretreatment size
of the tumor(s). A suggested template requisition
form that can be sent with the specimen is included
in Supplementary Information 2.
Specimen handling
Priorities for evaluation of the surgical specimen are
different after neoadjuvant systemic therapy, with
emphasis on informed and accurate evaluation of
tumor response to treatment. In general, one should
apply the principles within national and institu-
tional guidelines for standardization of processing
and reporting of breast specimens, such as those
noted above. Ideally, specimens should be sliced
when fresh to identify the markers of the original
tumor bed and to ensure formalin penetration.
Residual tumor is usually less well defined and
softer than untreated tumor, making it more difficult
to detect grossly. Therefore, careful mapping and
more extensive sampling is required for histopatho-
logic study. It is strongly recommended that an
image of the sliced specimen be recorded (radio-
graph, photograph, photocopy, or drawing) and then
used as a map for the sections taken, so that the
histopathologic findings of any residual disease in
the breast can be more easily understood. For
example, the sections taken can be drawn on a
printed image of the sliced specimen and then
scanned into the pathology database for viewing at
the time of histopathologic study. More precise
imaging of the gross specimen and correlation with
the histopathologic sections will decrease the num-
ber of sections taken from the breast, and increase
the efficiency and accuracy of pathologic assess-
ment. This can save time and money while enabling
consistent and careful pathologic interpretation. The
recommendations below will attempt to supplement
existing national guidelines for specific situations
encountered in the neoadjuvant setting; however, the
pathologist should use sound clinical judgment on a
case-by-case basis.
Sampling of small lumpectomy specimens. Many
institutional standard operating procedures call for
thinly slicing and submitting small specimens in
their entirety (e.g., o5 cm in greatest diameter in
Yale University’s standard operating procedure, and
o30 g in the Dutch national guideline26) in a manner
that allows reconstruction of the specimen at the
time of microscopic evaluation through accurate
description or with the help of a diagram. Unfortu-
nately, this approach does not allow for tissue
collection for research. Clinical judgment should be
applied in this setting. If there is obvious gross
residual tumor, then a research sample can be taken
without compromising accurate histological assess-
ment. In cases where the macroscopic findings are
nonspecific, or there is clinical doubt about the
location of the tumor bed, then consideration should
be given to submitting the entire specimen. Research
samples may still be taken by thinning the blocks and
submitting the trim, or, alternatively, small cylinders
of tissue can be taken with a punch biopsy tool.
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Depending on the type of processing used for the
research tissue, histology can still be evaluated if
deemed clinically necessary, such as hematoxylin
and eosin-stained sections of research blocks. A
previous international working group has addressed
the collection of research tissue in the neoadjuvant
setting in detail.43
It is important to document that these small
resections have adequately excised the lesion.
The tumor bed/clip must be identified. Tumor bed
extending to the margins should be documented.
Sampling of large lumpectomy/mastectomy speci-
mens (partial submission). Targeted representative
sections can be taken from larger specimens, but it is
essential to carefully and accurately represent the
tumor bed in a manner that can be retrospectively
mapped to the gross and/or radiologic findings. This
enables more accurate estimation of the extent of
residual disease. Correlation with clinical and
imaging findings is imperative to ensure the correct
area is sampled. Sampling should include grossly
visible tumor bed and/or the location of any marker
clips and immediately adjacent tissue to encompass
the area suspected of involvement by carcinoma
before treatment (Figure 3). This area to be sampled
is referred to as the pretreatment area of involvement
in the discussion below. Degree of sampling is then
determined by the pretreatment size in addition to
any visible tumor bed or grossly visible residual
disease.
Ideally, the specimen is sliced to reveal the largest
cross-section of the pretreatment area of involve-
ment. Block(s) representing the full face of the
pretreatment area of involvement should be taken
of every 1 cm slice containing pretreatment area of
involvement, or, for very large tumors, five repre-
sentative blocks of a cross-section of pretreatment
area of involvement per 1–2 cm of pretreatment size,
up to a total maximum of ∼25 blocks. In the absence
of trial-based evidence as to the degree of sampling
required, the committee felt this to be a pragmatic
approach that should be sufficient to determine the
presence of pathological complete response. The US
Food and Drug Administration, in their guidance,
have recommended taking ‘a minimum of one block
per cm of pre-treatment tumor size, or at least 10
blocks in total, whichever is greater’.34 The extent of
sampling should be guided by good clinical judg-
ment on a case-by-case basis—informed, directed
sampling is more important than blindly taking a
prescribed number of blocks. For assessment of
cellularity of very large tumor beds, five representa-
tive blocks are sufficient to represent the largest
Random sampling: 
Blue blocks = complete response 
Black blocks = residual disease
Inter-observer variability and 
discrepancies among guidelines 
regarding size
Slices
Slices
Slides
No residual tumor grossly
Tumor bed with clip 
identified
Tumor bed indistinct
Clip identified
Tumor bed with clip identified
Microscopic residual disease
No residual tumor
Microscopic residual disease
Size unchanged
Cellularity decreased
Size decreased
Cellularity similar
“Concentric shrinking”
Size changed or unchanged
Cellularity decreased, 
heterogeneous
Size changed or unchanged
Cellularity decreased, 
heterogeneous 
Large areas without 
residual disease and 
apparent multiple foci
“Scatter pattern”
Patterns of residual diseaseResidual tumor grossly
Gross size confirmed
Microscopic residual disease 
beyond grossly visible tumor
Microscopic tumor 
extends beyond grossly 
visible tumor bed.
1 2 3 4 5
Mapping of the specimen
Correlation with pre-treatment size/ imaging
Largest cross-section of tumor bed and estimate  
of cellularity in slice 3
Serial slices
Systematic sampling is appropriate
Black and blue rectangles represent 3 
random blocks of tumor, each with 
very different estimates of cellularity.
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Sampling has limits
1 2
Pre-treatment tumor
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Surgical specimen
Block for histologic evaluation
Clip
1 2
1 2
1 2
1 2 3 4 5
Histology slide
Figure 3 Problems related to sampling for histologic evaluation. Gross residual tumor may or may not be present after neoadjuvant therapy
(top left). Even when the tumor bed is entirely submitted, histologic evaluation has limits (top center). The blue and black slides represent
different levels obtained from the same block. The blue slides show a complete response. The black slides show minimal residual
microscopic disease. Partial response shows various patterns and the decrease in cellularity is often heterogeneous (right). In these cases,
random sampling of tumor can lead to very different estimates of tumor cellularity (bottom center). Random sampling with the blue blocks
would conclude a complete response. Random sampling with the black blocks would document residual disease. Often, the microscopic
tumor extends beyond a grossly visible tumor bed (bottom left). The largest cross-section of tumor bed is sampled for an estimate of tumor
cellularity.
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cross-section of residual tumor bed and calculate the
Residual Cancer Burden.45
Precise description must be used to allow recon-
struction of the specimen during histologic evalua-
tion for accurate measurements and cellularity
estimates. We strongly recommend visual images,
such as photographs, specimen radiographs, or
sketched diagrams, with annotations to indicate the
sites where tissue sections were taken for histo-
pathologic evaluation.
If no residual disease is seen on initial sections, or
if the distribution of the disease does not correspond
to the initial gross impression, then a second pass
may be needed to submit further blocks. Additional
blocks, including sections documenting margins,
should be obtained as with non-neoadjuvant
specimens.
Laboratories with access to large tissue cassettes
are encouraged to utilize this technique as a superior
method for mapping the residual tumor bed. Large
cassettes enable sampling of a bigger area with fewer
blocks, with the entire lesion often captured on a
single slide. This simplifies reconstruction of the
extent of residual disease, measurement of lesion
size, and examination of margins.46
In cases where the above cutoffs would not result
in submission of the entire tumor bed, remaining
tissue can be sampled for research. Areas with
grossly visible tumor can easily be sampled. Cases
where the above cutoffs result in submission of the
entire tumor bed can be sampled for research as
described in the section ‘Sampling of small lumpec-
tomy specimens’ under ‘Specimen handling’ above.
If only formalin-fixed, paraffin-embedded tissue is
needed, additional blocks can be submitted from a
second pass for research from areas that had residual
tumor on microscopy.
Multiple lesions in lumpectomy or mastectomy. In
specimens containing multiple lesions, each lesion
should be handled as a single lesion as described
under ‘Sampling of large lumpectomy/mastectomy
specimens (partial submission)’ above, with the
addition of blocks of tissue taken from in between
the lesions to ensure that they are truly separate and
to evaluate the presence of other intervening disease,
such as DCIS.
Microscopic reporting
Prognostic and predictive factors traditionally evalu-
ated in surgical specimens following primary surgery
are all relevant in the neoadjuvant systemic therapy
setting. Although some familiar prognostic information
may be altered by treatment (e.g., tumor grade and
histological type) or may be less reliable (lymph node
and margin status), much can be gained from the
opportunity to evaluate response to treatment.
Histologic tumor type and grade. The method for
determination of histologic tumor type and tumor
grade is identical to that used for non-neoadjuvant
specimens, although it is not clear whether these add
prognostic information to the pretreatment results.
Tumors with a typical appearance of no special type
before treatment may have a lobular growth pattern
following neoadjuvant chemotherapy.47 Treatment
can cause nuclear hyperchromasia and pleomorph-
ism; however, the findings should be compared with
the pretreatment biopsy before assuming they are
treatment-related. The mitotic rate may be reduced
by treatment; this finding is associated with a
better prognosis (disease-free survival and overall
survival)48 and lower risk of developing distant
metastases.49 Clonal heterogeneity within the tumor
may be reflected by variable response to therapy,
and by areas with different morphology and grade. A
comment regarding the presence of such heteroge-
neity should be made in the report, and is important
when choosing blocks for postneoadjuvant systemic
therapy hormone receptor and HER2 assessment.
If multiple, morphologically distinct tumors are
present that are clearly separated by adipose tissue,
they should be reported as separate lesions. How-
ever, it should be noted that the largest residual
primary tumor is used for determination of both
Residual Cancer Burden and yp stage. Note that ypT
stage is defined by the largest contiguous focus of
invasive cancer, whereas Residual Cancer Burden
uses the two dimensions of the largest residual area
of residual invasive cancer (i.e., that does not need to
be contiguous) in the tumor bed.
Size and extent. Tumor size/extent is often more
difficult to assess after neoadjuvant systemic ther-
apy. There are two main patterns of tumor response
following neoadjuvant systemic therapy—concentric
shrinking and the scatter pattern (Figure 3). Measure-
ment of lesion size in this latter scenario may be
difficult. Our suggested approach is described in
Table 1.
Cellularity. In addition to its effect on tumor size,
neoadjuvant systemic therapy often has a profound
effect on tumor cellularity. Tumor size may not
decrease, but overall cellularity may be markedly
reduced (Figure 3), making residual tumor cellularity
an important factor in assessing response.50 Com-
parison of pre- and post-treatment cellularity is the
key element of several systems for grading
response.7,13,15,42 If a formal classification system
for grading of response is used, this should be noted
in the report. As tumor cellularity is often hetero-
geneous, the pretreatment core biopsy may not be
representative of the entire tumor. Similarly, changes
in tumor cellularity induced by neoadjuvant sys-
temic therapy can be heterogeneous and therefore
more extensive sampling may be needed to accu-
rately assess cellularity. The descriptions of these
scoring systems do not explicitly state how to deal
with this heterogeneity, and it can be tempting only
to assess the most cellular areas of the tumor.
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Table 1 Controversial scenarios in reporting breast cancer after neoadjuvant systemic therapy
Scenario Current evidence/guidelines Suggested approach
Residual tumor present as
scattered foci (common)
• Tumor size is often more difficult to assess after
neoadjuvant treatment.
• Residual carcinoma may be present as
multiple, small foci scattered over a
(ill-defined) tumor bed.
• There are two main options to measure size in
this setting:
(A) Residual tumor bed size in two dimensions
(used to calculate the Residual Cancer
Burden score): the extent of the area
involved by all islands of residual invasive
tumor cells and intervening stroma. This
does not include tumor bed beyond the
area containing residual invasive tumor
cells.
(B) Tumor size according to American Joint
Committee on Cancer staging 7th edition67:
if the residual tumor consists of
microscopic nests in a fibrotic stroma, ypT
should be based on the largest contiguous
area of invasive carcinoma, with an
indication that multiple foci are present
(‘m’).
(A)
2 dimensions of largest 
cross-section of residual
tumor bed (entire area 
involved) 
(B)
Extent of largest 
contiguous focus
Tumor bed
• If there is a single lesion present on
pretreatment imaging, then regard residual
disease as a single tumor, especially if tumor
cells are present within a reactive stromal
background consistent with a solitary tumor
bed (Opinion).
• When there are scattered islands of tumor
cells, measurement (B) (diagram at left) as
described by American Joint Committee on
Cancer staging 7th edition67 may result in
significant underestimation of tumor extent.
There are also currently no data on the
relationship of measurement (B) to outcome
(Opinion).
• Lesion size including the cell clusters and
intervening fibrous tissue (A) (diagram at
left), which is congruent with the earlier, 6th
edition of American Joint Committee on
Cancer staging,68 correlates with survival69 and
may be more relevant, for example for com-
parison with radiology (Limited Evidence).
• In our opinion, the combination of residual
tumor cellularity and measurement (A) is the
better indicator of response (Opinion).
• When required to report American Joint
Committee on Cancer 7th edition stage, both
measurements (A) and (B) should be given
in the pathology report, with an explanation of
how the final size and stage designation was
made (Published Guideline).
• If there are multiple tumors present on
pretreatment imaging or tumor foci are
separated by normal breast tissue, then regard
as multiple lesions and measure
independently as distinct tumor foci.
Dimensions from the largest tumor deposit
should be used for ypTNM staging (Published
Guideline).
Presence of lymphovascular
invasion in the absence of an
identifiable residual invasive
tumor mass (rare)
• There are insufficient data on the independent
prognostic significance of the presence of
lymphovascular invasion or extensive
lymphovascular invasion in neoadjuvant
specimens.
• One small study found that such
intralymphatic tumor carries adverse
prognostic significance, even in the absence
of residual stromal invasion.70 However,
most of the patients also had residual
disease in the lymph nodes and multi-
variate analysis was not possible.
• Residual lymphovascular invasion should
NOT be classed as pathological complete
response—make a statement in the pathology
report that residual tumor is present in the
form of intravascular disease (Opinion).
• Ensure tumor bed has been accurately
localized and adequately sampled to exclude
residual invasive disease (Opinion).
• Ensure truly lymphovascular invasion, not
DCIS or retraction artifact. This may be
difficult; immunohistochemistry may be
helpful (Opinion).
• Measurement is optional. If a limited area is
involved, a measurement in mm can be
given. Alternatively, lymphovascular
invasion can be quantified as focal or
extensive with ‘extensive’ defined as one or
more foci in more than one block71 (Opinion).
• Although it was agreed residual
lymphovascular invasion should not be
regarded as pathological complete response, in
the absence of adequate data the working
group felt it was not appropriate to give
definite reporting recommendations (Opinion).
Presence of isolated tumor cells
in lymph nodes (common)
• American Joint Committee on Cancer TNM
recommends isolated tumor cells after
chemotherapy be called node negative
(ypN0itc) but not regarded as pathological
complete response.67
• Any residual disease in the lymph node,
including micrometastases and isolated
tumor cells, should NOT be classified as
pathological complete response (Limited
Evidence).
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The Residual Cancer Burden system does not
require pretreatment cellularity, but proposes stan-
dardized sampling of the specimen with assessment
of the average cellularity across the largest two-
dimensional area of residual tumor bed. For Residual
Cancer Burden, the tumor bed area is defined by the
two largest dimensions of gross tumor bed defined
by macroscopic examination with or without accom-
panying specimen radiography, but can be later
revised after these corresponding slides have been
reviewed under the microscope. Hence, the impor-
tance of accurate block description and advisability
of an illustrative map to determine how the slides
map to the gross tumor bed (described above). The
online cellularity standard provided in the Residual
Cancer Burden website45 and the images in the
publication for the Miller–Payne score are useful
aids for pathologists in estimating cellularity.15 The
presence or absence of residual DCIS, and the
percentage of residual tumor present as in situ
disease, should also be documented as per the
Residual Cancer Burden.
We advocate submitting the largest cross-section of
the residual tumor bed with the relevant sections
noted in the pathology report.
Lymphovascular invasion. The presence or
absence of lymphovascular invasion should be
documented (Figure 4). There are insufficient data
on the independent prognostic significance of lym-
phovascular invasion in neoadjuvant specimens. See
Table 1 for suggested approaches to assessing and
reporting lymphovascular invasion.
Margins. In cases with variable response leading to
multiple, small foci of residual disease in a subtle
tumor bed, carcinoma may extend beyond an
apparently negative margin. Tumor bed extending
to the margins, and which margin is involved,
should be documented (Figure 5).
Evaluation of the axilla after treatment
Several studies have shown that posttreatment nodal
status is an important determinant of disease-free
survival and overall survival, regardless of response
within the breast.32,35–40 Currently, lymph node
staging in patients who have received neoadjuvant
systemic therapy is usually performed by either
Figure 4 Extensive lymphovascular space invasion after che-
motherapy. In this case, an invasive tumor focus was not identified
despite extensive sampling. The axillary nodes were positive for
residual metastatic carcinoma (courtesy of Elena Provenzano).
Table 1 (Continued)
Scenario Current evidence/guidelines Suggested approach
• World Health Organization recommends
isolated tumor cells after chemotherapy be
called node positive.72
• Findings include:
• Disease-free survival and overall survival
worsened with increasing number of nodes
and deposit size. Size of largest metastasis
was strongest predictor of overall survival in
multivariate analysis. Micrometastatic
disease o2mm, including isolated tumor
cells, was predictive of worse outcome.40
• No difference in relapse-free survival and
overall survival between groups when size of
the largest residual metastatic deposit was
classified as ≤0.1 cm, 0.1–1 cm, and ≥1 cm
in patients with proven axillary nodal
disease before neoadjuvant chemotherapy.39
• No change in prognosis with occult
metastases identified by
immunohistochemical staining for
cytokeratins.73
• If no associated fibrosis, treat as in adjuvant
setting and call node negative (Opinion).
• If associated fibrosis present, the likelihood
is this represents previous micro- or
macrometastasis with response. A comment
should be included regarding the presence of
chemotherapy effect, and the size of the
entire area, including tumor cells and
intervening stroma, should be measured,
rather than the size of the largest cell cluster
(Limited Evidence).
• Additional levels and/or immunohisto-
chemistry are not routinely required.
However, immunohistochemistry may be
useful if suspicious cells are identified on
hematoxylin and eosin, and levels can be
used to clarify the size of a deposit if isolated
tumor cells/micrometastasis are present on
the initial section (Limited Evidence).
Limited Evidence = consensus opinion of committee based on limited evidence; Opinion= consensus opinion of committee in the absence of
reliable evidence.
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sentinel lymph node biopsy or axillary lymph node
dissection. The accuracy of sentinel lymph node
biopsy for staging postneoadjuvant systemic therapy
is still under investigation, especially in patients
with clinically positive nodes before treatment.44,51
The paradigm in surgical management of the axilla
is evolving,34 and is the subject of ongoing
investigation.44,51 This is reflected in the use of the
phrase ‘sampled regional lymph nodes’ by the US
Food and Drug Administration in its proposed
definition of pathological complete response.34
The procedure for evaluating sentinel lymph nodes
and axillary lymph nodes should be the same as for
non-neoadjuvant specimens. All surgically removed
lymph nodes should be sectioned at 2mm intervals
and entirely submitted for histologic evaluation. Some
special considerations apply, however.
Some studies have indicated a lower number of
lymph nodes identified at axillary lymph node
dissection after neoadjuvant systemic therapy,
whereas others have found no significant difference
following careful pathological evaluation.52–54
Pathologists evaluating axillary lymph node dissec-
tion tissue should subject any tissue that may
represent lymph node for microscopic evaluation.
The size of the largest metastatic deposit should be
measured microscopically and the presence or
absence of any extranodal extension documented.
Postneoadjuvant systemic therapy tumor cells are
often present as scattered single cells within an area
of reactive stromal changes or lymphoid tissue.
When measuring the size of the metastasis in this
context, the size of the area that is even partly
involved by metastatic tumor should be measured,
and not just the size of the largest tumor cluster.
Clearly separate smaller foci in a node are not
included in the maximum size measurement. As
micrometastases and isolated tumor cells found after
neoadjuvant systemic therapy are predictors of
worse survival, specimens with nodal micrometas-
tases or isolated tumor cells should not be designated
as having pathological complete response.40,55 Our
suggested approach to assessing isolated tumor cells
in this context is provided in Table 1.
The presence of treatment effect in the lymph
nodes in the form of fibrosis (Figure 6), mucin pools,
or large aggregates of foamy histiocytes identifies a
subset of patients with an outcome intermediate
between that of completely node negative and node
positive after neoadjuvant systemic therapy.56 How-
ever, small fibrous scars in lymph nodes can also be
seen in patients without treatment, and in patients
who have had a previous biopsy it can be impossible
to reliably distinguish biopsy site changes from
regressed metastasis.57 Previously involved nodes
Figure 6 Lymph node showing zonal areas of fibrosis after chemotherapy indicative of metastasis with response to therapy (courtesy of
Elena Provenzano). (a) Low-power image of lymph node showing zonal fibrosis indicating site of metastasis. (b) On higher magnification of
a different node, residual islands of tumor cells are present in a setting of reactive fibrosis with hemosiderin-laden macrophages,
consistent with chemotherapy effect.
Figure 5 Tumor bed present at the resection margin (courtesy of
Frédérique Penault-Llorca).
Modern Pathology (2015) 28, 1185–1201
Postneoadjuvant breast cancer evaluation
1194 E Provenzano et al
may also look completely normal after treatment.
The latter scenario can cause concern when there
was histologically proven metastasis before treat-
ment, but evidence of a positive node cannot be
found in the final surgical specimen. In this setting,
the specimen (including axillary tail, if a mastec-
tomy) should be carefully reexamined to ensure all
nodes have been retrieved, and the patient reexam-
ined, before assuming there has been complete
response. Clipping the involved node before treat-
ment can also be of value in determining nodal
response.
In some centers, sentinel lymph nodes are
assessed by molecular assays (e.g., one-step nucleic
acid amplification) without any morphological eval-
uation. This does not allow assessment of response
in the node; moreover, one-step nucleic acid ampli-
fication is usually not calibrated to detect isolated
tumor cells.58 Therefore, we do not recommend the
use of these techniques in the neoadjuvant setting.
Pathological complete response
Our group agrees with the following core principle of
the definition of pathological complete response as
proposed by the US Food and Drug Administration:
‘Pathological complete response is defined as the
absence of residual invasive cancer on…. evaluation
of the complete resected breast specimen and all
sampled regional lymph nodes following completion
of neoadjuvant systemic therapy.’34 However, we
advocate that the presence of invasive tumor cells is
considered residual disease regardless of the method
of detection—that is, hematoxylin and eosin or
immunohistochemistry—although the latter is not
routinely recommended. The alternative definition,
requiring absence of both DCIS and invasive carci-
noma in the breast, can also be used. The definition
of pathological complete response chosen should be
agreed between pathologists and clinicians within
individual institutions, and clearly stated in the
report. If the patient is enrolled in a clinical trial, the
definition of pathological complete response pre-
scribed by the trial standard operating procedure
should be included as part of the report with an
explanatory note. Regardless of which definition is
used, the presence/absence and extent of residual
DCIS should be reported as detailed in our recom-
mended template (Table 2).
Microscopically, the tumor bed may be identified
as a focal area of loose, edematous reactive stroma
with a variable inflammatory cell infiltrate that may
include collections of lipid or hemosiderin-laden
macrophages, lymphocytes, and plasma cells. Back-
ground breast lobules often appear hyalinized and
atrophic with a perilobular lymphocytic infiltrate.
We would like to stress the following. Accurate,
reproducible documentation of pathological com-
plete response requires adequate sampling of the
correct area of the breast. Overly exhaustive sam-
pling and histologic evaluation of the entire tumor
bed are generally not required and are far less
valuable than intelligent mapping of the correct
locations within the specimen. Therefore, correla-
tion of clinical and imaging information and markers
of the tumor site with gross pathology of the
specimen are indispensible.
Retesting of markers in the postneoadjuvant therapy
specimen
Reassessment of hormone receptor and HER2 status in
residual cancer after neoadjuvant systemic therapy is
variable between individual centers, with no consen-
sus regarding if and when retesting of markers is
advisable. The clinical utility of reassessing marker
status in the surgical specimen may depend on the
results from the core biopsies taken before neoadjuvant
systemic therapy. If retesting is performed, it may be
done on either the residual primary tumor or residual
nodal disease if the latter contains a better representa-
tion of residual tumor cells. Our recommendations are
provided in Table 3.
Finally, in some centers, assessment of Ki67
labeling index is performed before and after neo-
adjuvant systemic therapy. Posttreatment Ki67
index has been shown to correlate with long-term
outcome after both neoadjuvant endocrine59 and
chemotherapy,60,61 although its routine use in
clinical practice has not yet been formally recom-
mended because of lack of standardization in its
assessment.62–64 Proliferation is commonly reduced
by neoadjuvant systemic therapy and hence, in
addition to Ki67, results of multigene assays that
include proliferation genes may also change if
assessed before and after treatment.65
Minimum data set to be reported by pathologists
A suggested summary template for reporting neoad-
juvant systemic therapy specimens is presented in
Table 2, with minimum data set items highlighted.
The US National Cancer Institute’s Breast Oncology
Local Disease (BOLD) Task Force has also recom-
mended standardized data elements for collection in
preoperative breast cancer clinical trials.66
Conclusion
Postneoadjuvant systemic therapy histopathological
changes are complex, and careful systematic review
of the specimen is required for accurate diagnosis
and follow-up treatment. For pathological complete
response to be used as an indicator of response to
novel therapies, it is essential to have a standardized
way in which residual disease is measured and
reported. We designed the recommendations speci-
fically for the clinical trial setting; however, they can
be optionally incorporated into routine practice
because, in our opinion, standardization is
most effective when uniformly applied. Hopefully,
such standardization will improve our knowledge
and ability to compare outcomes, promote the
submission of specimens for translational research,
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Table 2 Suggested template for reporting breast cancer specimens after neoadjuvant systemic therapy in clinical trialsa
Pretreatment
Pretreatment core biopsy findings (where available)
Histological tumor type
Pretreatment histological grade
(Pretreatment cellularity)
Presence/absence of DCIS
Hormone receptor and HER2 status
(Ki67, multigene assays)
Type of neoadjuvant treatment: chemotherapy, hormone therapy, radiotherapy, chemo+radiotherapy
Type of procedure
Breast: (wide local excision ± localization, mastectomy, other)
Lymph nodes: (sentinel lymph nodes, axillary dissection, other lymph nodes, eg, internal mammary)
Laterality: (left, right, not specified)
Macroscopy
Residual macroscopic tumor identified: yes/ no
If residual macroscopic tumor:
Site of tumor (upper outer, lower outer, upper inner, lower inner, central)
Unifocal vs multifocal
If multifocal, number of foci
Size of macroscopic lesion(s): _ x _ x _ mm
If no residual macroscopic tumor:
Area of fibrosis present: yes/ no
Site of fibrosis
Size of fibrosis: _ x _ x _ mm
Radiological marker identified: yes/no/not present
Microscopy
Size/extent of residual tumor: _ mm
Largest cross-section of residual tumor bed (entire area involved) _ x _ mm represented in cassettes (….)
Posttreatment histological grade
Residual cellularity:__%
DCIS: present/absent
Total lesion size including DCIS: _ x _ mm
Percentage of residual cellularity that is CIS:__%
Lymphovascular space invasion: present/absent/indeterminate/extensive
In the absence of residual tumor, is the previous tumor site identified (clip site/area of fibrosis): yes/no
Margin status
Invasive carcinoma: present/absent; distance to closest margin
DCIS: present/absent; distance to closest margin
Tumor bed: present/absent
Lymph node status
Number of sentinel/axillary lymph nodes
Number of sentinel/axillary lymph nodes with metastases
Size of largest metastasis
Evidence of treatment response in the metastases: present/absent
Number of lymph nodes with evidence of treatment response (e.g., fibrosis or histiocytic infiltrate) but no tumor cells
Presence (extent) of extracapsular extension
Final classification of chemotherapy response
Grade of response and classification system used
If no formal grading system used, minimum comment regarding response as below:
Breast:
Pathological Complete Response
Residual invasive carcinoma, no definite response
Residual invasive carcinoma with probable or definite response to chemotherapy
*If there is more than one tumor with variable response between lesions, then the poorest level of response should be taken as the overall
classification.
Lymph nodes:
Metastasis present, no response
Metastasis present, evidence of response
No residual metastasis but evidence of previous metastasis with response
No metastasis or fibrosis (true negative)
ypTN stage
Repeat marker testing:
ER/PR/HER2 if initial biopsy was negative or equivocal
(Ki67)
Abbreviations: CIS, carcinoma in situ; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor.
aBold items indicate suggested minimum data set specific to postneoadjuvant specimens, IN ADDITION to minimum required for other types of
specimens.
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and facilitate the more timely introduction of new
agents.
The recommendation of this committee is that
pathologic reports of residual disease after neoadjuvant
chemotherapy and/or targeted therapy in clinical trials
should include the following information:
 Pathological Complete Response or Residual Dis-
ease. This should separately describe whether
there was residual invasive cancer in the breast,
in situ cancer in the breast, and the pathologic
status of the regional lymph nodes.
 Residual Cancer Burden as the preferred method
for more detailed quantification of residual
disease. The report should provide the final residual
tumor dimensions, cellularity of cancer in the final
tumor bed area and the proportion of in situ
component within that cancer, and the number of
positive nodes and the size of the largest metastasis,
as well as the Residual Cancer Burden score
and class.
 ypTN Stage. The report should separately report
the ypT and ypN stages and the pathologist should
use the most current edition of the American Joint
Committee on Cancer/Union for International
Cancer Control staging definitions when evaluat-
ing tumor size after neoadjuvant chemotherapy.
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